Psoriasis: a new adverse event of ibrutinib

Ital J Dermatol Venerol. 2024 Apr;159(2):205-207. doi: 10.23736/S2784-8671.23.07735-6. Epub 2024 Jan 29.

Authors

Luca Rapparini^{1

2}, Alice Massi^{3

2}, Carlotta Baraldi¹, Gabriele Gugliotta⁴, Alessandro Pileri^{1

2}

Affiliations

¹ Unit of Dermatology, University Hospital of Bologna, Bologna, Italy.
² Department of Medical and Surgical Sciences, Alma Mater Studiorum, Bologna, Italy.
³ Unit of Dermatology, University Hospital of Bologna, Bologna, Italy - alice.massi@studio.unibo.it.
⁴ Unit of Hematology, University Hospital of Bologna, Bologna, Italy.

PMID: 38287741
DOI: 10.23736/S2784-8671.23.07735-6

No abstract available

Publication types

Letter
Case Reports

MeSH terms

Adenine* / adverse effects
Adenine* / analogs & derivatives
Aged, 80 and over
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Male
Piperidines* / adverse effects
Piperidines* / therapeutic use
Psoriasis* / chemically induced
Psoriasis* / drug therapy
Pyrazoles* / adverse effects
Pyrazoles* / therapeutic use
Pyrimidines* / adverse effects
Pyrimidines* / therapeutic use

Substances

Adenine
ibrutinib
Piperidines
Pyrazoles
Pyrimidines